GlassScriptPhysician profile
Donald I Baumstein
NPI 1902974447
$4,939.82
in general payments reported to CMS, 2019-2025
14 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $29.12 · 2021: $15.65 · 2022: $4,382 · 2023: $27.74 · 2024: $87.33 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $4,314.26 | 2020-2022 | |
| Genzyme Corporation | $141.02 | 2019 | |
| Amgen INC. | $107.85 | 2022-2023 | Parsabiv, Tavneos |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Ceribell, INC. | $59.90 | 2025 | Pocket Eeg Device |
| Kestra Medical Technology Services, INC. | $46.19 | 2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $41.68 | 2019-2020 | |
| Ardelyx, INC. | $34.38 | 2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $27.73 | 2024 | Lupkynis |
| Vifor Pharma, INC. | $25.22 | 2024 | Veltassa |
| Pfizer INC. | $18.04 | 2019 | |
| Merck Sharp & Dohme LLC | $16.46 | 2025 | Keytruda, Lynparza |
| Rockwell Medical, INC. | $16.45 | 2019 | |
| Glaxosmithkline, LLC. | $15.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Baumstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.